2025年指导 销售额：56亿 - 60亿美元（按不变汇率计算增长8% - 10%） TAVR：41亿 - 44亿美元（按不变汇率计算增长5% - 7%） TMTT：5亿 - 5.3亿美元（按不变汇率计算增长50% - 60%） 外科手术：9.7亿 - 10.5亿美元（按不变汇率计算增长中等个位数增长） 外汇对销售的影响：约1亿美元的不利影响（报告增长率下降约2点） 调整后毛利润率：78% - 79% 调整后运营利润率：27% - 28% 税率：15% - 18% 调整后每股收益：2.40 - 2.50美元 摊薄股份总数：5.85 - 5.95亿 预计2026年及以后的结构性心脏治疗法贡献增加；目标是公司销售额年均增长10%和每股收益两位数增长 主要来源于EARLY TAVR和PROGRESS驱动的TAVR中高个位数增长 TMTT对增长的贡献增加，预计到2030年达到20亿美元 包括结构性心力衰竭和AR在内的新治疗领域的贡献增加

以上内容来自Benzinga Earnings专栏，原文如下：

2025 Guidance

Sales	$5.6 - $6.0 billion (8% - 10% constant currency growth)
TAVR	$4.1 - $4.4 billion (5% - 7% constant currency growth)
TMTT	$500 - $530 million (50% - 60% constant currency growth)
Surgical	$970 million - $1.05 billion (mid-single digit constant currency growth)
FX Impact on Sales	~$100 million unfavorable (~2pt downside to reported growth)
Adjusted Gross Profit Margin	78% - 79%
Adjusted Operating Margin	27% - 28%
Tax Rate	15% - 18%
Adjusted EPS	$2.40 - $2.50
Diluted Shares Outstanding	585 – 595 million

• Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth
  • Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS
  • TMTT increasing contribution to growth, reaching $2 billion by 2030
  • Increasing contribution from new therapeutic areas including Structural Heart Failure and AR